Earnings call · Apr–Jun 2026
IOL Chemicals & Pharmaceuticals Ltd
IOL reported Apr–Jun 2026 revenue of ₹756 crore (37% growth from a year earlier) & PAT of ₹64.5 crore (90% growth). Non-ibuprofen APIs reached 43% of pharma revenue & grew 67% from a year earlier. Management guides FY27 revenue growth of 15-20% & EBITDA margin of 14-15%.
The full notes: the guidance, numbers & KPIs, strategy, outlook, risks, what analysts asked.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
From the company
- Prachi AmbreMufg Investor Relations
- Abhay Raj SinghSenior Vice President
- Pardeep Kumar KhannaChief Financial
- Rakesh MahajanFinance Advisor and
- Kushal Kumar RanaDirector Works
- Shaikh Mohammed
Questions came from
- Abu RafeWealth Catalyst
- Pahel SharmaDD Capital
- VigneshSequent Scientific
- Surabhi SutariaNV Alpha
- Jainam GhelaniSvan Investments
- SantoshLGT Capital
- SoumyaNirva Securities
- Maulik Varia360 ONE Mutual Fund
- Nimish VermaAAS Capital
- Sheikh Mohammed
- Abhishek KamdarValue Plus Advisors
- Santosh ShettyLSG Capital
Topics in this call
Opening remarks
Abhay Raj SinghSenior Vice President
Thank you so much, Prachi, for the introduction. Good afternoon, everyone, and welcome to the Q1 FY27 earnings call of IOL Chemicals and Pharmaceuticals Limited. Thank you for joining us today and for your continued trust and support. I hope you have had an opportunity to review our financial results and investor presentation, filed with the stock exchanges and also available on our websites.
We have started FY27 on a strong note, with healthy demand across key products, improved capacity utilization, favorable product mix, and continued focus on operational efficiency. In the pharmaceutical division, we continue to make good progress in diversifying our API portfolio beyond ibuprofen, with healthy demand across key products including paracetamol, pantoprazole, metformin, fenofibrate, and clopidogrel, etcetera.
Read the whole call: 166 paragraphs, 12 analysts' questions with every answer, 6 marked passages.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript the company filed on BSE as scanned pages, read into text by AI (Claude): a word may be misread, so check the original PDF for anything important. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.